Here, we investigated the effect of IGF-I on NASH and cirrhotic animal models and demonstrate IGF-I ameliorated steatosis, inflammation, and fibrosis. This evidence concerns the gene IGF1 and metabolic dysfunction-associated steatohepatitis.